Eric Kapitbahay, BSN, RN, works on the 7 South Dialysis unit of Vanderbilt University Hospital. He is one of the latest DAISY Award winners at VUMC.

The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.

The project will create the Urinary Stone Disease Hub, known as USDHub, with de-identified patient data from over 230,000 individuals with kidney stone disease across nine health systems in the U.S.

Thiazide diuretics are commonly prescribed to prevent kidney stone recurrence, treat high blood pressure, and clear fluid from the body in conditions such as heart failure.

A kidney protein that responds to low levels of blood potassium — which can cause high blood pressure and cardiovascular problems — may be a target for new therapeutics.

Researchers at Vanderbilt University Medical Center have identified Rac1, a molecular switch that regulates the actin cytoskeleton of epithelial cells in the collecting ducts, as a driver of post-obstructive kidney repair.

Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.